Overall Status

Not yet recruiting (1)

Recruiting (1)

Withdrawn (1)

Phase

phase 1 (2)

phase 1/phase 2 (1)

Sponsor

City of Hope Medical Center (2)

Helsinn Healthcare SA (1)

Collaborator

National Cancer Institute (NCI) (2)

Labcorp Drug Development Inc (1)

Intervention

chlorotoxin (eq)-cd28-cd3zeta-cd19t-expressing car t-lymphocytes (via ict delivery) (1)

chlorotoxin (eq)-cd28-cd3zeta-cd19t-expressing car t-lymphocytes (via ict/icv dual delivery) (1)

infigratinib (1)

neural stem cells-expressing crad-s-pk7 (1)

resection (1)

Study Documents

Intervention Type

biological (2)

drug (1)

procedure (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

recurrent who grade ii glioma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma Trial in Duarte

Withdrawn

Recurrent Anaplastic Astrocytoma
+7 more

Neural Stem Cells-expressing CRAd-S-pk7
Resection

(no location specified)

Nov 22, 2022

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting

Advanced Solid Tumor
+2 more

Infigratinib

Palo Alto, California
+9 more

Aug 2, 2022

Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin

Recruiting

Recurrent Glioblastoma
+3 more

Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)

Duarte, California

City of Hope Medical Center

Feb 25, 2022